Haemonetics Corporation
Rank #192HypergrowthHAE · NYSE · Healthcare
Haemonetics Corporation (HAE) — Rank #192 by gross profitability (GP/assets 0.33) · ROE 11.6% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0000313143 · all metrics point-in-time as of the filing date.
About
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions.
Show moreShow less
The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors.
The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- April 3
- Website
- haemonetics.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2020-03-28filed 2020-05-20 | 2019-03-30filed 2019-05-22 | 2018-03-31filed 2019-05-22 | 2017-04-01filed 2019-05-22 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 110.3 | 109.4 | 89.2 | 89.7 |
| Stock-based compensation | 20.5 | 17.2 | 13.0 | 9.2 |
| Change in receivables | (18.9) | 38.1 | (5.1) | (3.2) |
| Change in inventory | 84.7 | 39.3 | (14.4) | 1.6 |
| Operating cash flow | 158.2 | 159.3 | 220.4 | 159.7 |
| Investing | ||||
| Capital expenditures | 48.8 | 119.0 | — | — |
| Acquisitions, net of cash | — | — | — | — |
| Investing cash flow | (57.2) | (116.1) | (63.0) | (73.3) |
| Financing | ||||
| Debt issued | 0.0 | 347.8 | 0.0 | 0.0 |
| Debt repaid | 13.1 | 266.9 | 61.7 | 42.7 |
| Share repurchases | 175.0 | 160.0 | 100.0 | 0.0 |
| Financing cash flow | (131.2) | (50.6) | (120.6) | (60.4) |
| Summary | ||||
| Free cash flow | 109.5 | 40.3 | 40.3 | 40.3 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?